News | July 19, 2021
Lonza extends collaboration with Biopharma company
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Subscribe To Our Newsletter & Stay Updated
